David Clayton
Psychiatry · Fairfax, VANPI 1992866883
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 802 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,069, 2.8 times the $1,080 reported in 2019. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 802 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Supernus Pharmaceuticals, Inc.$931
- Ironshore Pharmaceuticals Inc.$885
- Tris Pharma Inc$857
- plus $8K from 26 others
What the payments were for
- Food & beverage$14,35799%
- Education$2071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 81 | $1,425 |
| AbbVie(2 entities) | 85 | $1,401 |
| Otsuka America Pharmaceutical, Inc. | 72 | $1,129 |
| Supernus Pharmaceuticals, Inc. | 43 | $931 |
| Ironshore Pharmaceuticals Inc. | 46 | $885 |
| Tris Pharma Inc | 59 | $857 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $854 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $844 |
| Bausch Health US, LLC | 44 | $779 |
| Johnson & Johnson | 33 | $653 |
| Vanda Pharmaceuticals Inc. | 20 | $617 |
| Sunovion Pharmaceuticals Inc. | 34 | $617 |
| Teva Pharmaceuticals USA, Inc. | 24 | $552 |
| Corium, LLC | 28 | $493 |
| Alkermes, Inc. | 19 | $352 |
| Neos Therapeutics, LP | 25 | $332 |
| Collegium Pharmaceutical, Inc. | 14 | $288 |
| Neurocrine Biosciences, Inc. | 11 | $273 |
| Shire North American Group Inc | 20 | $248 |
| Axsome Therapeutics, Inc. | 12 | $226 |
| Aytu Biopharma, Inc. | 1 | $215 |
| Adlon Therapeutics L.p. | 11 | $158 |
| Idorsia Pharmaceuticals US Inc | 8 | $138 |
| E.r. Squibb & Sons, L.L.C. | 5 | $91 |
| Almatica Pharma LLC | 3 | $60 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Eisai Inc. | 2 | $25 |
| Noven Therapeutics, LLC | 1 | $20 |
| Noven Pharmaceuticals, Inc. | 1 | $20 |
| TMS Neurohealth Centers Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adzenys XR-ODT$215
- QELBREE$191
How this compares
$14,565 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Wellbutrin XlBupropion Hcl | 20 | $47,928 |
| VraylarCariprazine Hcl | 12 | $16,246 |
| Xanax XrAlprazolam | 13 | $4,622 |
| Aripiprazole | 52 | $4,296 |
| Citalopram HbrCitalopram Hydrobromide | 24 | $2,920 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $2,806 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $1,766 |
| Clozapine | 20 | $1,279 |
| Bupropion XlBupropion Hcl | 43 | $980 |
| Risperidone | 18 | $791 |
| Escitalopram Oxalate | 61 | $581 |
| Fluoxetine Hcl | 19 | $452 |
| Olanzapine | 20 | $443 |
| Quetiapine Fumarate | 26 | $426 |
| Ziprasidone Hcl | 13 | $420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,401 | $16,24612 claims |
| Almatica Pharma LLCSertraline Hcl | $60 | $6012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Fairfax
- Ifeanyi OleleFairfax$100K
- Maria TsaoFairfax$11K
- Alok KumarFairfax$9K
- Siddharth BajpaiFairfax$8K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- David SpiegelNorfolk$565K
- William YetterVirginia Beach$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.